Mattias Mandorfer
A5001144757- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Organ Transplantation Techniques and Outcomes
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Hepatitis Viruses Studies and Epidemiology
- Protease and Inhibitor Mechanisms
- Drug-Induced Hepatotoxicity and Protection
- Endoplasmic Reticulum Stress and Disease
- Peptidase Inhibition and Analysis
- Pancreatitis Pathology and Treatment
- Hormonal Regulation and Hypertension
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Alcohol Consumption and Health Effects
- Renal function and acid-base balance
- COVID-19 Clinical Research Studies
- HIV-related health complications and treatments
- Blood Coagulation and Thrombosis Mechanisms
- Abdominal vascular conditions and treatments
- Electrolyte and hormonal disorders
- Systemic Sclerosis and Related Diseases
- Trace Elements in Health
Medical University of Vienna
2016-2025
Montavid Thermodynamic Research Group
2020-2025
Vienna General Hospital
2022-2024
ERN GUARD-Heart
2022-2024
Universitat de Barcelona
2020-2023
University of Bologna
2023
University of Modena and Reggio Emilia
2023
RWTH Aachen University
2022
Edinburgh Royal Infirmary
2022
University of Edinburgh
2022
•Patients with acutely decompensated cirrhosis without ACLF develop 3 different clinical courses.•Patients pre-ACLF within 90 days and have high systemic inflammation mortality.•Patients unstable suffer from complications of severe portal hypertension.•Patients stable less frequent lower 1-year mortality risk. Background & AimsAcute decompensation (AD) is defined as the acute development ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof,...
Acute decompensation (AD) of cirrhosis may present without acute-on-chronic liver failure (ACLF) (AD-No ACLF), or with ACLF (AD-ACLF), defined by organ failure(s). Herein, we aimed to analyze and characterize the precipitants leading both these AD phenotypes. The multicenter, prospective, observational PREDICT study (NCT03056612) included 1,273 non-electively hospitalized patients (No = 1,071; 202). Medical history, clinical data laboratory were collected at enrolment during 90-day...
•Baseline serum AFP ≥100 ng/ml and CRP ≥1 mg/dl were independently associated with worse OS in ICB-treated patients HCC.•A score based on these two variables predicts disease control rate overall survival HCC.•The was validated an independent cohort of HCC.•In sorafenib-treated HCC, the prognostic for but not predictive rate. Background & AimsImmunotherapy atezolizumab plus bevacizumab represents new standard care systemic front-line treatment hepatocellular carcinoma (HCC). However,...
INTRODUCTION: We aimed to explore the prevalence of portal hypertension in most common etiologies patients with compensated advanced chronic liver disease (cACLD) and develop classification rules, based on stiffness measurement (LSM), that could be readily used diagnose or exclude clinically significant (CSPH) clinical practice. METHODS: This is an international cohort study including paired LSM/hepatic venous pressure gradient (HVPG), LSM ≥10 kPa, no previous decompensation. Portal was...
Sustained virologic response (SVR) to interferon (IFN)-free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into clinical benefit. We assessed the impact pretreatment HVPG, changes and posttreatment HVPG on development decompensation patients with PH who achieved SVR IFN-free therapy. Moreover, we evaluated transient elastography (TE) von Willebrand factor platelet...
•Progression of portal hypertension severity (reflected by HVPG) occurs mostly across compensated ACLD stages.•Systemic inflammation CRP and IL-6 levels) substantially increases only decompensated ACLD.•IL-6 levels are independent predictors first decompensation in death/liver transplantation ACLD. Background & AimsDistinct prognostic stages advanced chronic liver disease (ACLD) defined (PH) the presence/absence clinical complications. We characterised degree dysfunction, PH, systemic...
Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in patients with advanced chronic liver disease (ACLD) caused by hepatitis C who have achieved sustained virologic response (SVR). We developed risk stratification algorithms for de novo HCC development after SVR validated them an independent cohort.We evaluated the occurrence derivation cohort 527 pre-treatment ACLD to interferon-free therapy, whom alpha-fetoprotein (AFP) non-invasive surrogates portal hypertension...
Alpha1-antitrypsin (AAT) deficiency results from carriage of a homozygous SERPINA1 "Z" mutation (proteinase inhibitor [PI] ZZ). The Z allele produces mutant AAT protein called Z-AAT, which accumulates in hepatocytes and can lead to progressive liver disease fibrosis. This open-label, phase 2 trial investigated the safety efficacy fazirsiran, an RNA interference therapeutic, patients with associated deficiency.
Liver stiffness measurements (LSMs) provide an opportunity to monitor liver disease progression and regression noninvasively. We aimed determine the prognostic relevance of LSM dynamics over time for liver-related events death in patients with chronic disease.Patients undergoing 2 or more reliable LSMs at least 180 days apart were included this retrospective cohort study stratified baseline (BL) as nonadvanced (non-ACLD, BL-LSM < 10 kPa), compensated ACLD (cACLD; ≥ decompensated ACLD. Data...
Background & Aims Liver stiffness measurements (LSM) are recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, LSM changes predict decompensation mortality in patients with alcohol-related liver (ALD). Methods Observational cohort study of compensated at risk ALD from Denmark Austria. the all-cause mortality, stratified advanced chronic (cACLD: Baseline ≥10 kPa) after a median 2 years. In cACLD, we defined as (A) increase ≥20% ("cACLD...
Transient elastography (TE) can non-invasively diagnose cirrhosis and portal hypertension (PHT). New TE reliability criteria suggest classifying measurements as very reliable (IQR/M < 0.1), (IQR<0.3 or >0.3, if 7.1 kPa) poorly > 0.3, kPa). Compare traditional (reliable: success rate >60% + IQR/M ≤ 0.30) new quality (accurate: reliable) regarding their diagnostic accuracy for PHT to identify potential confounders (age, aetiology, necroinflammatory activity, steatosis, siderosis, cholestasis,...
The Billroth III guidelines were developed during a consensus meeting of the Austrian Society Gastroenterology and Hepatology (ÖGGH) Interventional Radiology (ÖGIR) held on 18 February 2017 in Vienna. Based international considering recent landmark studies, recommendations aim to help physicians guiding diagnostic therapeutic strategies patients with portal hypertension.
•Total cross-sectional SPSS area (TSA) predicts survival in patients with advanced chronic liver disease.•The cut-off for TSA that is associated worse corresponds to a single shunt of >10 mm diameter.•This study may impact on the clinical use TSA/SPSS risk stratification and decision-making management cirrhosis. Background & AimsSpontaneous portosystemic shunts (SPSS) frequently develop Recent data suggested presence large complications, especially overt hepatic encephalopathy (oHE)....
Objective Homozygous alpha1-antitrypsin (AAT) deficiency increases the risk for developing cirrhosis, whereas relevance of heterozygous carriage remains unclear. Hence, we evaluated impact two most relevant AAT variants (‘Pi*Z’ and ‘Pi*S’), present in up to 10% Caucasians, on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse. Design We analysed multicentric case–control cohorts consisting 1184 people biopsy-proven NAFLD 2462 chronic misuse, both comprising cases...